Mohamed Abbas, A., M.M., A., El Naggar, H., El-Dek, S., Farghali, A., Fekry El Kersh, M. (2022). Using a Novel Nanoparticle as An Adjuvant for Inactivated Avian Influenza Vaccine. Journal of Applied Veterinary Sciences, 7(1), 31-37. doi: 10.21608/javs.2021.100437.1110
Amani Mohamed Abbas; Abd El-Moneam M.M.; H.M. El Naggar; S.I. El-Dek; A.A. Farghali; Mohamed Fekry El Kersh. "Using a Novel Nanoparticle as An Adjuvant for Inactivated Avian Influenza Vaccine". Journal of Applied Veterinary Sciences, 7, 1, 2022, 31-37. doi: 10.21608/javs.2021.100437.1110
Mohamed Abbas, A., M.M., A., El Naggar, H., El-Dek, S., Farghali, A., Fekry El Kersh, M. (2022). 'Using a Novel Nanoparticle as An Adjuvant for Inactivated Avian Influenza Vaccine', Journal of Applied Veterinary Sciences, 7(1), pp. 31-37. doi: 10.21608/javs.2021.100437.1110
Mohamed Abbas, A., M.M., A., El Naggar, H., El-Dek, S., Farghali, A., Fekry El Kersh, M. Using a Novel Nanoparticle as An Adjuvant for Inactivated Avian Influenza Vaccine. Journal of Applied Veterinary Sciences, 2022; 7(1): 31-37. doi: 10.21608/javs.2021.100437.1110
Using a Novel Nanoparticle as An Adjuvant for Inactivated Avian Influenza Vaccine
1Veterinary Serum and Vaccine Research Institute, Abbasia, Agricultural Research Center, Cairo, Egypt.
2Material Science and Nanotechnology Department, Faculty of Postgraduate studies for advanced sciences, Beni- Suef University, Beni- Suef, Egypt.
3Animal Health Research Institute, Dokki, Agricultural Research Center, Giza, Egypt.
Receive Date: 11 October 2021,
Revise Date: 25 November 2021,
Accept Date: 01 December 2021
Abstract
The present work evaluated the mesoporous silica nanoparticles (MSNs) as a promising adjuvant in preparation of inactivated avian influenza H9N2 vaccine in chicken. Two inactivated vaccine formulae were prepared by using Montanide™ ISA 71 VG and MSNsas adjuvants. Both vaccine formulae were found to be sterile and safe from local or systemic post-vaccinal reactions. Regarding the vaccine potency, it was found that antibody titer against H9N2 strain was detected in chickens of the group (2) that received the inactivated H9N2 vaccine with MSNs adjuvant and the highest antibody titer (9.6 log2) was detected early at both 2nd and 3rd-week post-vaccination using haemagglutination inhibition test. On the other hand, the antibody titer against the H9N2 virus in chickens of group (1) vaccinated with the inactivated H9N2 vaccine adjuvanted with Montanide ISA 71 was (5.3 log2 and 8.6 log2) at 2nd and 3rd-week post-vaccination respectively and reached its maximum value at 4th-week post-vaccination (9.0 log2). The results of viral shedding in group (1) vaccinated by Montanide ISA 71 H9N2 vaccine showed only virus shedding of 9.3 × 102 EID50 and Ct value of 35.53 2nd day post-challenge (DPC) using Real-time RT-PCR. While in group (2) received MSNs and H9N2 vaccine detected no virus shedding at 2nd DPC, later viral shedding was detected at a rate of 2.4×102 (Ct value of 24,24) and 4.2×102 (Ct value of 26.77) at 4th and 6th DPC respectively in comparison with the control unvaccinated group (3) that had the highest virus shedding value ranged from 3.5×107 (Ct value of 20.34) at 2nd DPC to 3.08×106 (Ct value of 23.92) at 6th DPC. The present work proved the efficacy of silica nanoparticles as a possible adjuvant for inactivated Avian Influenza H9N2 vaccine.
ABOUAITAH, K., A.A. FARGHALI, A. SWIDERSKA-SRODA, W. LOJKOWSKI, A.-F. RAZIN, and M. KHEDR, 2016. pH- Controlled release system for curcumin based on functionalized dendritic mesoporous silica nanoparticles, J. Nanomed. Nanotechnol, (7)351. DOI:10.4172/2157-7439.1000351.
ADRIANUS, C.M., and RICHARD, J.W., 2009. “Antigenic cross-reactivity among H5N1 viruses" Chapter-2. Cited in vaccines for pandemic influenza. Book. Edited by Richard W. Compans and Walter A. Orenstein.
ALI, M., YAQUB, T., MUKHTAR, N., IMRAN, M., GHAFOOR, A., SHAHID, M.F., YAQUB, S., SMITH, G.J.D., SU, Y.C.F., and NAEEM, M., 2018. Prevalence and phylogenetics of H9N2 in backyard and commercial poultry in Pakistan. Avian Diseases, 62(4): 416-424.
ALLAN, W.H., LANCASTER, J.E., and TOTH, B., 1978. Newcastle disease vaccines their production and use. FAO Animal Production and Health Series No. 10. FAO: Rome, Italy.
BEN SHABAT, M., MEIR, R., HADDAS, R., LAPIN, E., SHKODA, I., RAIBSTEIN, I., PERK, S., and DAVIDSON, I., 2010. Development of a real-time TaqMan RT-PCR assay for the detection of H9N2 avian influenza viruses. J Virol Methods.168 (1-2):72-7. DOI: 10.1016/j.jviromet.2010.04.019. Epub 2010 May 6.
BHARTI, C., NAGAICH, U., PAL, A.K., and GULATI, N., 2015. Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharm Investig. 5(3):124-133. DOI:10.4103/2230-973X.160844.
CODE OF AMERICAN FEDERAL REGULATION CFR., 2019. Office of the Federal Register National Archives Records Service. Animals and Animal products. Ch. 111. Office of the federal register National Archives Records Administration, USA.
DELANY, I., RAPPUOLI, R., and DE, G.E., 2014. Vaccines for the 21st Century. EMBO Mol Med 6:708–720. DOI: 10.1002/emmm.201403876.
EL-MASRY, I., RIJIKS, J., PEYRE, M., TYLOR,N., LUBROTH, J., JOBER, Y., 2014. Modeling influenza A H5N1 vaccination strategy scenarios in the house hold poultry setaries in Egypt. Topical animal health and production. 46 (1): 57-63.
EL-ZOGHBY, EF, ARAFA, AS, HASSAN, MK, ALY, MM, SELIM, A., KILANY, W.H., SELIM, U., NASEF, S., AGGOR, M.G., ABDELWHAB, E.M., and HAFEZ, H.M., 2012. Isolation of H9N2 avian influenza virus from bobwhite quail (Colinus virginianus) in Egypt. Arch. Virol., 157(6): 1167-1172. DOI: 10.1007/s00705-012-1269-z. Epub 2012 Mar 17.
LIU, Z., RU, J., SUN, S., TENG, Z., DONG, H., SONG, P., and GUO, H.,2019. Uniform dendrimer-like mesoporous silica nanoparticles as a nano-adjuvant for foot-and-mouth disease virus-like particle vaccine. Journal of Materials Chemistry B, 7(21), 3446-3454. DOI:10.1039/C8TB03315C.
MERCURI, LP., CARVALHO, L.V., LIMA, F.A., QUAYLE, C., and FANTINI, M.C., 2006. Ordered mesoporous silica SBA-15: a new effective adjuvant to induce antibody response. Small 2:254–256.
DOI: 10.1002/smll.200500274.
NAGUIB, M.M., VERHAGEN, J.H., SAMY, A., ERIKSSON, P., FIFE, M., LUNDKVIST, Å, ELLSTRÖM, P., and JÄRHULT, J.D., 2019. Avian influenza viruses at the wild-domestic bird interface in Egypt. Infect. Ecol. Epidemiol., 9(1): 1575687. d o i: 10.1080/20008686.2019.1575687
OIE TERRESTRIAL., 2019. Chapter 3.3.4.
SOOYEON K, SINGH, R.K., and WOJCIECH, C., 2013. Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng. 4:1–35. DOI: 10.1177/2041731413503357.
SPSS. 2006. SPSS for windows releases 14.0.0,12 June 2006. standard version, copyright SPSS Inc.1989-2006 All right reserved, copy right®SPSS.
SWAYNE, DE; SPAKMAN, E., and PANTIN-JACWOOD, M., 2014. Success factor for avian influenza vaccine use in poultry and potential impact at wild bird-agriculturalinterface. Ecohealth. 11 (1): 94-108.
SYAMSIAH AINI S., LEOW B.L.,FAIZUL FIKRI M.Y., MUHAMMAD REDZWAN S., ONG G.H., and FAIZAH HANIM M.S., 2019. Genetic analysis of h9n2 avian influenza viruses isolated from chickens in Malaysia from 2015- 2018. Malaysian Journal of Veterinary Research. Volume 10 no. 2. 79-92
TREWYN BG, SLOWING II, GIRI S, CHEN H.T., and LIN VS., 2007. Synthesis and functionalization of a mesoporous silica nanoparticle-based on the sol-gel process and applications in controlled release. Acc Chem Res. 40:846-53. DOI.org/10.1021/ar600032u.
ZONGXI LI, JONATHAN C. BARNES, ALEKSANDR BOSOY, J. FRASER STODDART and JEFFREY I. ZINK, 2012. Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev., 41, 2590-2605. DOI: 10.1039/c1cs15246g.
View on SCiNiTO
Top